Embattled German conglomerate Bayer, which reduced its workforce by 3,200 positions in the first half of the year, has reportedly announced further layoffs this week as it continues to navigate its financial and operational challenges. In a setback for Aadi, the company's plans to widen the use of its key drug were derailed by disappointing results from a phase II solid tumor trial. Meanwhile, on the regulatory front, the FDA has approved updated COVID-19 vaccines that target KP.2 strain to enhance protection this fall. Additionally, Johnson & Johnson made headlines by expanding its MedTech cardiovascular portfolio through a new acquisition, marking a significant move in its growth strategy.
Let's dive into the details.
For comments and feedback: editorial@rttnews.com